CNS/Neurology market research reports by Global Markets Direct

• Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Dec 28, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and He ... Read More

• Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Dec 28, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical ... Read More

• Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Dec 28, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Meningitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide ... Read More

• Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Nov 30, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member ... Read More

• Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Drugs In Development, 2022, provides an overview of the Pontine Glioma (Oncology) p ... Read More

• Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Drugs In Development, 2022, provides an overview of the Gliosarcoma (Oncology) pipeline l ... Read More

• Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2022, provides an overview of the Anaplastic ... Read More

• Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Drugs In Development, 2022, provides an overview of the Neuroblastoma (Oncology) pipe ... Read More

• Progressive Multifocal Leukoencephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Progressive Multifocal Leukoencephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2022, ... Read More

• Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Sep 30, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Drugs In Development, 2022, provides an overview of the Schizophrenia (Central Nervou ... Read More

• Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Sep 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Drugs In Development, ... Read More

• Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Sep 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Drugs In Development, 2022, provides an overview of the Migraine (Central Nervous System) pipel ... Read More

• Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Sep 30, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Drugs In Development, 2022, provides an overview of t ... Read More

• Narcolepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Jul 29, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Narcolepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Drugs In Development, 2022, provides an overview of the Narcolepsy (Central Nervous System) ... Read More

• Guillain-Barre Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Jul 29, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Guillain-Barre Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Drugs In Development, 2022, provides an overview of the Guillain- ... Read More

• Tinnitus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Jun 30, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Tinnitus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus – Drugs In Development, 2022, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pi ... Read More

• Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  May 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Drugs In Development, 2022, provides an overview of the Mild ... Read More

• Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  May 31, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subun ... Read More

• Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  May 31, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Drugs In Development, 2022, provides an overview of the Depression (Central Nervous System) ... Read More

• 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  May 31, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report '5-Hydroxytryptamine Receptor 7 - Drugs In Developmen ... Read More

• Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  May 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2022, provides an overview of the Opium ( ... Read More

• Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Mar 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Drugs in Development by Stages, Targe ... Read More

• Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Mar 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) ... Read More

• Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Mar 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Drugs in Development by Stages, Target, Mo ... Read More

• Meniere Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Mar 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Meniere Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, ... Read More

< prev 1 2 next >